These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Sánchez-Galán E; Gómez-Hernández A; Vidal C; Martín-Ventura JL; Blanco-Colio LM; Muñoz-García B; Ortega L; Egido J; Tuñón J Cardiovasc Res; 2009 Jan; 81(1):216-25. PubMed ID: 18852255 [TBL] [Abstract][Full Text] [Related]
25. Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays. Yan D; Stocco R; Sawyer N; Nesheim ME; Abramovitz M; Funk CD Mol Pharmacol; 2011 Feb; 79(2):270-8. PubMed ID: 21078884 [TBL] [Abstract][Full Text] [Related]
26. Leukotrienes mediate 5-hydroxytryptamine-induced plasma extravasation in the rat knee joint via CysLT-type receptors. Wang Y; Mitchell J; Sharma M; Gabriel A; Moriyama K; Palmer PP Inflamm Res; 2004 Feb; 53(2):66-71. PubMed ID: 15021971 [TBL] [Abstract][Full Text] [Related]
27. Genetics and pharmacogenetics of the leukotriene pathway. Tantisira KG; Drazen JM J Allergy Clin Immunol; 2009 Sep; 124(3):422-7. PubMed ID: 19665766 [TBL] [Abstract][Full Text] [Related]
28. Leukotriene synthases and the receptors induced by peripheral nerve injury in the spinal cord contribute to the generation of neuropathic pain. Okubo M; Yamanaka H; Kobayashi K; Noguchi K Glia; 2010 Apr; 58(5):599-610. PubMed ID: 19908283 [TBL] [Abstract][Full Text] [Related]
29. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Bäck M Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386 [TBL] [Abstract][Full Text] [Related]
30. Advances in eicosanoid research, novel therapeutic implications. Haeggström JZ; Rinaldo-Matthis A; Wheelock CE; Wetterholm A Biochem Biophys Res Commun; 2010 May; 396(1):135-9. PubMed ID: 20494126 [TBL] [Abstract][Full Text] [Related]
32. [The role of leukotrienes and the effect of leukotriene receptor antagonists in allergic rhinitis]. Kupryś I; Kuna P Pol Merkur Lekarski; 2000 Oct; 9(52):717-20. PubMed ID: 11144066 [TBL] [Abstract][Full Text] [Related]
33. Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis. Mirshafiey A; Jadidi-Niaragh F Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):219-27. PubMed ID: 20298145 [TBL] [Abstract][Full Text] [Related]
34. The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. Norel X; Brink C Pharmacol Ther; 2004 Jul; 103(1):81-94. PubMed ID: 15251228 [TBL] [Abstract][Full Text] [Related]
35. Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells. Yudina Y; Parhamifar L; Bengtsson AM; Juhas M; Sjölander A Prostaglandins Leukot Essent Fatty Acids; 2008 Dec; 79(6):223-31. PubMed ID: 19042113 [TBL] [Abstract][Full Text] [Related]
36. [Modulation of leukotriene pathway - potential targets]. Peter H; Lýdia B Ceska Slov Farm; 2012 Jun; 61(3):101-6. PubMed ID: 22913825 [TBL] [Abstract][Full Text] [Related]
38. [Leukotriene receptor antagonists--possible therapeutic option in the treatment of atopic dermatitis ]. Czarnecka-Operacz M; Jenerowicz D Pol Merkur Lekarski; 2003 Jan; 14(79):86-8. PubMed ID: 12712839 [TBL] [Abstract][Full Text] [Related]
39. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Berger W; De Chandt MT; Cairns CB Int J Clin Pract; 2007 Apr; 61(4):663-76. PubMed ID: 17394438 [TBL] [Abstract][Full Text] [Related]
40. The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders. Jo-Watanabe A; Okuno T; Yokomizo T Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336653 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]